These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 35296468)
21. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM; Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917 [TBL] [Abstract][Full Text] [Related]
22. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome. Meo SA; Shaikh N; Abukhalaf FA; Meo AS Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276 [TBL] [Abstract][Full Text] [Related]
23. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698 [TBL] [Abstract][Full Text] [Related]
24. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. Jarius S; Bieber N; Haas J; Wildemann B J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110 [TBL] [Abstract][Full Text] [Related]
25. Risk of Bell's palsy following SARS-CoV-2 infection: a nationwide cohort study. Kim HJ; Jeong S; Song J; Park SJ; Oh YH; Jung J; Choi NK; Park SM Clin Microbiol Infect; 2023 Dec; 29(12):1581-1586. PubMed ID: 37611865 [TBL] [Abstract][Full Text] [Related]
26. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Kaulen LD; Doubrovinskaia S; Mooshage C; Jordan B; Purrucker J; Haubner C; Seliger C; Lorenz HM; Nagel S; Wildemann B; Bendszus M; Wick W; Schönenberger S Eur J Neurol; 2022 Feb; 29(2):555-563. PubMed ID: 34668274 [TBL] [Abstract][Full Text] [Related]
27. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967 [TBL] [Abstract][Full Text] [Related]
28. Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study. Morciano C; Massari M; Cutillo M; Belleudi V; Trifirò G; Mores N; Sapigni E; Puccini A; Zanoni G; Zorzi M; Monaco G; Leoni O; Del Zotto S; Samez S; Mayer F; Marano G; Menniti Ippolito F; Da Cas R; Traversa G; Spila Alegiani S Drug Saf; 2024 Nov; 47(11):1157-1169. PubMed ID: 39068268 [TBL] [Abstract][Full Text] [Related]
29. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M BMJ; 2021 May; 373():n1088. PubMed ID: 33985964 [TBL] [Abstract][Full Text] [Related]
30. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236 [TBL] [Abstract][Full Text] [Related]
32. Left Bell's palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report. Cellina M; D'Arrigo A; Floridi C; Oliva G; Carrafiello G Clin Imaging; 2022 Feb; 82():1-4. PubMed ID: 34763263 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN; Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358 [TBL] [Abstract][Full Text] [Related]
35. Bell's Palsy and COVID-19: Insights from a Population-Based Analysis. Balchander D; Cabrera CI; Qureshi H; Perez JA; Goslawski A; Tranchito E; Johnson BR; Tamaki A; Rabbani CC Facial Plast Surg Aesthet Med; 2024; 26(1):41-46. PubMed ID: 37751178 [No Abstract] [Full Text] [Related]
36. Bell's palsy and COVID-19: A cohort study with historical rate comparison. Arango N; Rojas-Lechuga MJ; Chen J; Larrosa F; Alegre B; Vilaseca I Acta Otorrinolaringol Esp (Engl Ed); 2024 Sep; ():. PubMed ID: 39306084 [TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
38. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190 [TBL] [Abstract][Full Text] [Related]
40. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports. Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]